AARD.NASDAQAardvark Therapeutics, INC

10-Q: Aardvark Therapeutics Reports First Quarter 2025 Financial Results, Highlights Phase 3 Clinical Trial Progress

Sentiment:

Quarterly Report

📋All filings for Aardvark Therapeutics, INC
🔒Login to Follow

Aardvark Therapeutics announces its financial results for the first quarter of 2025, emphasizing the advancement of its Phase 3 clinical trial for ARD-101 in Prader-Willi Syndrome.

Worse than expectedThe company's net loss increased significantly in Q1 2025 compared to Q1 2024, indicating a worsening financial performance.Research and development expenses increased significantly, indicating higher spending but not yet translated into revenue.

Summary

  • Aardvark Therapeutics, Inc. reported a net loss of $9.31 million for the three months ended March 31, 2025, compared to a net loss of $2.18 million for the same period in 2024.
  • Research and development expenses increased to $7.76 million from $1.21 million year-over-year, driven by higher external costs for CMC, clinical, and toxicology studies related to ARD-101.
  • General and administrative expenses rose to $2.72 million from $0.86 million, primarily due to increased legal, professional costs, and costs associated with operating as a public company.
  • The company completed its IPO in February 2025, raising net proceeds of approximately $87.5 million.
  • As of March 31, 2025, Aardvark had cash, cash equivalents, and short-term investments totaling $151.3 million, which is expected to fund operations into 2027.
  • Aardvark is currently focused on developing ARD-101, an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen, for hyperphagia associated with Prader-Willi Syndrome (PWS).
  • The company initiated a Phase 3 clinical trial for ARD-101 in December 2024 and anticipates topline data in early 2026.
  • Aardvark also intends to evaluate ARD-101 in a Phase 2 clinical trial for hyperphagia associated with hypothalamic obesity (HO).

Sentiment

Score: 6

Explanation: The sentiment is neutral. While the company has made progress in its clinical development programs and has a solid cash position, it is also experiencing increasing losses and faces significant risks and challenges in the biopharmaceutical industry.

Positives

  • The company successfully completed its IPO, providing substantial capital for ongoing and planned activities.
  • Existing cash, cash equivalents, and short-term investments are projected to fund operations into 2027.
  • A Phase 3 clinical trial for ARD-101 in PWS is underway, with topline data expected in early 2026.
  • The company is expanding its clinical management and regulatory capabilities.

Negatives

  • The company experienced a significant increase in net loss for Q1 2025 compared to Q1 2024.
  • The company has a limited operating history and no products approved for commercial sale.
  • The company identified a material weakness in its internal control over financial reporting.
  • The company has written off $2.368 million related to Aardwolf Therapeutics, Inc.

Risks

  • The company's business is heavily dependent on the successful development, regulatory approval, and commercialization of ARD-101.
  • Clinical trials may fail to demonstrate the safety and efficacy of product candidates.
  • The company relies on third parties to conduct clinical trials and manufacture drug supplies.
  • The company faces substantial competition in the biopharmaceutical industry.
  • The company identified a material weakness in its internal control over financial reporting.
  • The company may be affected by unfavorable economic conditions and challenges in the United States and abroad, such as the effects of the ongoing geopolitical conflicts in Ukraine, the Israel-Hamas war, tensions in U.S.-China relations, changes in tariff rates and the implementation of any trade barriers, disruptions in the banking industry and inflationary trends.

Future Outlook

The company believes its cash, cash equivalents, and short-term investments will be sufficient to fund operations into 2027 and plans to finance future cash needs through equity offerings, debt financings, or other capital sources.

Management Comments

  • Based upon our current operating plans, we believe that our existing cash, cash equivalents and short-term investments will be sufficient to fund our projected operations into 2027.

Industry Context

Aardvark Therapeutics is operating in the competitive biopharmaceutical industry, focusing on metabolic diseases and hunger-associated conditions. The company's approach of targeting Bitter Taste Receptors (TAS2Rs) is a novel strategy. The success of ARD-101 and ARD-201 will depend on their ability to demonstrate superior efficacy and safety compared to existing and emerging therapies.

Comparison to Industry Standards

  • Aardvark Therapeutics is a clinical-stage biopharmaceutical company, and its financial metrics should be compared to similar companies in the industry.
  • Comparable companies include Soleno Therapeutics, Rhythm Pharmaceuticals, Acadia Pharmaceuticals, Eli Lilly, Novo Nordisk, Roche, Pfizer, AstraZeneca, Boehringer Ingelheim, Amgen, Zealand Pharma, Viking Therapeutics, Altimmune, Terns Pharmaceuticals, Merck and Structure Therapeutics.
  • Aardvark's cash runway into 2027 is a positive indicator, but its increasing net losses and R&D expenses are areas to monitor.
  • The company's success will depend on the clinical trial outcomes of ARD-101 and ARD-201, as well as its ability to secure regulatory approvals and commercialize its products effectively.

Related Party Transactions

  • Family members of the Company's Chief Executive Officer are investors in the Company and owned an aggregate of 1,975,323 shares of common stock as of March 31, 2025.
  • The Company's Chief Executive Officer is a member of the board of directors of Aardwolf Therapeutics, Inc.

Stakeholder Impact

  • Shareholders: Dilution may occur from future equity offerings.
  • Employees: Job security is dependent on the company's financial performance and clinical trial outcomes.
  • Patients: Potential access to new treatments for metabolic diseases.
  • Suppliers: Increased business opportunities as the company expands its operations.

Next Steps

  • Continue Phase 3 clinical trial for ARD-101 in PWS and anticipate topline data in early 2026.
  • Evaluate ARD-101 in a Phase 2 clinical trial for hyperphagia associated with hypothalamic obesity (HO).
  • Seek to discover and develop additional product candidates.
  • Scale up clinical, operational, regulatory and quality assurance capabilities.
  • Establish a commercialization infrastructure and scale up external manufacturing and distribution capabilities to commercialize any product candidates for which we may obtain regulatory approval.

Key Dates

DateDescription
May 17, 2017Aardvark Therapeutics, Inc. was incorporated in the State of Delaware
May 31, 2022The Company contributed certain assets with a fair value of $ 0.2 million to a newly formed wholly-owned subsidiary, Aardwolf Tx, LLC
August 2022Aardwolf issued to the Company a convertible promissory note (the Aardwolf Note) with a principal amount of $ 1.0 million.
August 2023The FDA granted us an Orphan Drug Designation for the use of ARD-101 in PWS
October 2024The Company incorporated a wholly-owned subsidiary, Artisan Therapeutics, Inc., in the State of Delaware and contributed certain assets to the new entity.
December 2024The Companys board of directors adopted the 2025 Equity Incentive Plan (the 2025 Plan)
December 2024We began to take steps to address the material weakness through our remediation plan
December 2024We initiated a potentially pivotal Phase 3 HERO clinical trial in hyperphagia associated with PWS
January 2025The Companys board of directors adopted the 2025 Employee Stock Purchase Plan (the ESPP)
February 5, 2025The Company effected a one-for-8.474 reverse stock split of its common stock
February 11, 2025The 2025 Plan, pursuant to which 2,150,000 shares were initially reserved for issuance, became effective
February 11, 2025The ESPP became effective
February 14, 2025All outstanding shares of convertible preferred stock were converted into 11,439,838 shares of the Companys common stock and the Companys certificate of incorporation was amended and restated
February 2025The Company completed its IPO with the sale of 6,120,661 shares of common stock at an initial public offering price of $ 16.00 per share
March 31, 2025The Company had an accumulated deficit of $ 67.6 million
April 2025The first offering period under the ESPP commenced
May 1, 2025The number of shares of Registrants common stock outstanding as of May 1, 2025 was 21,695,920
August 11, 2025End of lock-up period for directors, executive officers and holders of substantially all of our outstanding securities
Early 2026Anticipated topline data from Phase 3 clinical trial

Keywords

ARD-101, Prader-Willi Syndrome, Hyperphagia, Clinical Trial, TAS2R, IPO, Aardvark Therapeutics, Financial Results, Biopharmaceutical, Research and Development

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.